Myomo Appoints Dr. Harry Kovelman as Chief Medical Officer

Nov. 2, 2020 13:30 UTC


Experienced Physician, Author and Executive to Join Senior Leadership Team


CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Harry Kovelman, MD, is joining the Company as its Chief Medical Officer, effective November 2. In this role, Dr. Kovelman will oversee Myomo’s patient advocacy organization, which helps ensure MyoPro patients’ clinical qualification for the brace and pursues insurance coverage. At Myomo, he will work closely with commercial and government payer organizations to continue to increase patient access to the MyoPro product line.

Dr. Kovelman brings 25 years of experience in medical devices and pharmaceuticals, including roles as Global Medical Director for Orthopedics at Ottobock Healthcare and Global Medical Affairs Director for Dynasplint Systems. He has also held senior executive roles at Pacira Pharmaceuticals, and Helius Medical Technologies.

He is the author of several papers on rehabilitation procedures and has presented at numerous professional conferences on various innovations in healthcare products and services. As a member of the company’s senior leadership team, Dr. Kovelman will lead communicating the Company's scientific message to the payer community, clinicians, and patients, lead medical activities and educational programs, participate in designing clinical studies of the Company’s products, and manage its Scientific Advisory Board of leading clinical professionals in the fields of rehabilitation medicine, occupational therapy, neurology and pediatric medicine.

Paul R. Gudonis, Myomo CEO, said, “I’m pleased to welcome Dr. Kovelman to Myomo as we continue to expand patient access to our life-changing technology, add to our clinical research, and educate additional medical professionals about the MyoPro product line. I’d also like to thank Dr. Brandon Green who has served in this role for the last four years and is fully supporting the transition in this Chief Medical Officer position.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit

Forward Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including benefits expected from this appointment and the Company’s goal to expand patient access to its products, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

  • our sales and commercialization efforts;
  • our ability to achieve reimbursement from third-party payers for our products;
  • our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;
  • our ability to effectively execute our business plan and scale up our operations;
  • our expectations as to our development programs; and
  • general market, economic, environmental and social factors, including the ongoing COVID-19 pandemic, that may affect the evaluation, fitting, delivery and sale of our products to patients.

More information about these and other factors that potentially could affect our financial results is included in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.


For Myomo:

Investor Relations:
Kim Sutton Golodetz
LHA Investor Relations

Public Relations:
Kate McCann
Matter Communications


Source: Myomo, Inc.

Back to news